Clinical Trial Update: Safety, Tolerability, PK, PD, and Immunogenicity of QL2401 in Healthy Chinese Adults [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of QL2401 in healthy Chinese adults for Metabolic dysfunct…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis

Drugs mentioned

• QL2401

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Metabolic Dysfunction-Associated Steatohepatitis(MASH) | Phase 1 | Status: NOT_YET_RECRUITING